Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus
Metrics: PDF 702 views | HTML 1805 views | ?
Anton Oseledchyk1,2, Jacob M. Ricca1,2, Mathieu Gigoux1,2, Brian Ko1,2, Gil Redelman-Sidi3,4, Tyler Walther1,2, Cailian Liu1,2, Gopa Iyer3,4, Taha Merghoub1,2,4,5, Jedd D. Wolchok1,2,3,4,5 and Dmitriy Zamarin1,2,3,4,5
1Ludwig Collaborative Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA
2Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA
3Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
4Weill Cornell Medical College, New York, NY, USA
5Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Dmitriy Zamarin, email: Zamarind@mskcc.org
Keywords: NDV; bladder cancer; lysis; immunotherapy; PD-1
Received: April 25, 2018 Accepted: May 31, 2018 Published: June 19, 2018
Intratumoral therapy with oncolytic viruses is increasingly being explored as a strategy to potentiate an immune response against cancer, but it remains unknown whether such therapy should be restricted to cancers sensitive to virus-mediated lysis. Using Newcastle Disease Virus (NDV) as a model, we explore immunogenic potential of an oncolytic virus in bladder cancer, where existing immunotherapy with PD-1 and PD-L1-targeting antibodies to date has shown suboptimal response rates. Infection of human and mouse bladder cancer cells with NDV resulted in immunogenic cell death, activation of innate immune pathways, and upregulation of MHC and PD-L1 in all tested cell lines, including the cell lines completely resistant to NDV-mediated lysis. In a bilateral flank NDV-lysis-resistant syngeneic murine bladder cancer model, intratumoral therapy with NDV led to an increase of immune infiltration in both treated and distant tumors and a shift from an inhibitory to effector T cell phenotype. Consequently, combination of intratumoral NDV with systemic PD-1 or CTLA-4 blockade led to improved local and abscopal tumor control and overall survival. These findings encourage future clinical trials combining intratumoral NDV therapy with systemic immunomodulatory agents and underscore the rationale for such treatments irrespective of tumor cell sensitivity to NDV-mediated lysis.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.